Medicine and Dentistry
Breast Cancer
75%
Cohort Analysis
33%
Recurrent Disease
23%
Premenopause
17%
Hormone Therapy
16%
Tamoxifen
16%
Malignant Neoplasm
13%
Case-Control Study
11%
Cancer Incidence
10%
Hazard Ratio
9%
Odds Ratio
9%
Estrogen Receptor
9%
Single Nucleotide Polymorphism
8%
Drug Therapy
8%
Adjuvant Endocrine Therapy
7%
Docetaxel
6%
Biological Marker
6%
Recurrence Risk
6%
Adjuvant Therapy
5%
Estrogen Receptor Positive Breast Cancer
5%
Standardized Incidence Ratio
5%
Survivin
5%
Childhood Cancer
5%
Phthalic Acid
5%
Aromatase Inhibitor
5%
Patient Compliance
5%
Adjustment Disorder
5%
Drug Prescription
5%
Typical Antipsychotic
5%
Metabolism
5%
Hypoxia Inducible Factor 1
5%
Meta-Analysis
5%
Systematic Review
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Cohort Study
31%
Recurrent Disease
30%
Tamoxifen
21%
Endocrine Therapy
16%
Statin (Protein)
13%
Malignant Neoplasm
12%
Case-Control Study
11%
Phthalic Acid
10%
Cancer Incidence
10%
Aromatase Inhibitor
10%
Estrogen Receptor
9%
Chemotherapy
9%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
7%
Estrogen Receptor Positive Breast Cancer
7%
Biological Marker
7%
Docetaxel
6%
Recurrence Risk
6%
Cancer Prognosis
5%
Taxane
5%
Survivin
5%
Typical Antipsychotic
5%
Childhood Cancer
5%
Hypoxia Inducible Factor 1
5%
Placebo
5%
Atorvastatin
5%
Biochemistry, Genetics and Molecular Biology
Cohort Study
22%
Premenopause
12%
Estrogen Receptor
12%
Metabolic Pathway
11%
Single-Nucleotide Polymorphism
10%
Genetic Divergence
10%
Case-Control Study
6%
All Cause Mortality
6%
Apolipoprotein B
5%
Hypoxia Inducible Factor 1
5%
Standardized Incidence Ratio
5%
Cancer Incidence
5%
Medical Record
5%
Survivin
5%
Lipid
5%
Body Mass
5%
CYP2D6
5%
